Hosted on MSN43m
Blockbuster weight-loss drugs linked to lower risk of addiction, schizophrenia, dementia, and moreBlockbuster weight loss drugs can help treat ailments as disparate as addiction, blood clotting, and dementia – but they also ...
The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
The data set from the double-blind phase of the RewinD-LB trial presented today at ILBDC is now accessible in the Investor section o the CervoMed website https://www.cervomed.com/.
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...
A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
1d
Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...
My 89-year-old husband was diagnosed with Alzheimer’s disease. He does not take any medication. He is in excellent health except for the Alzheimer’s. His blood pressure is 123/69 mm Hg, and his pulse ...
Kennedy Jr. was pressed to clarify his views on vaccines, abortion and public health priorities in the first of two senate ...
Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...
The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback